Market Place
Sourcing Support
Azurity Pharmaceuticals Announces FDA Approval of Nymalize Oral Solution
03 Sep 2024 //
PR NEWSWIRE
Azurity Pharmaceuticals` MYHIBBIN™ gets FDA approval.
06 May 2024 //
PR NEWSWIRE
Enforcement Report - Week of February 7, 2024
07 Feb 2024 //
FDA
Drug mix-up prompts Azurity to recall 1 lot of Zenzedi
26 Jan 2024 //
FIERCE PHARMA
Enforcement Report - Week of January 10, 2024
10 Jan 2024 //
FDA
Azurity Pharmaceuticals Acquires Slayback Pharma
27 Sep 2023 //
PR NEWSWIRE
Enforcement Report - Week of April 12, 2023
12 Apr 2023 //
FDA
Brand Institute Partners for FDA Approved Treatment for Gastric Ulcer
07 Sep 2022 //
PRNEWSWIRE
Azurity continues its win streak as it bags another approval from the FDA
03 Sep 2022 //
ENDPTS
US FDA grants approval for Azurity’s Konvomep to treat gastric ulcer
02 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
AZURITY PHARMA ANNOUNCES FDA APPROVAL OF ZONISADE (zonisamide oral suspension)
18 Jul 2022 //
PRNEWSWIRE
Azurity Pharmaceuticals Announces Richard Blackburn as New CEO
18 Feb 2022 //
PRNEWSWIRE
US FDA approves Azurity Pharma’s Fleqsuvy for spasticity from multiple sclerosis
08 Feb 2022 //
PHARMABIZ
FDA approves Eton-Azurity’s Eprontia oral solution for seizures and migraines
09 Nov 2021 //
PHARMACEUTICAL-TECHNOLOGY
Eton Pharma and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA™
08 Nov 2021 //
GLOBENEWSWIRE
AZURITY ANNOUNCES FDA APPROVAL OF EPRONTIA oral solution
08 Nov 2021 //
PRNEWSWIRE
Enforcement Report - Week of October 13, 2021
13 Oct 2021 //
FDA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.